Prelude Therapeutics appoints new director from Baker Bros.; shareholders approve increase in authorized shares

Prelude Therapeutics Inc

Appointed Paul Scherer, M.D. (Baker Bros. Advisors) as Class III director; granted options for 76,000 shares vesting over one year.
Stockholders elected Martin Babler and Victor Sandor as Class II directors for three-year terms at 2025 annual meeting.
Ratified Ernst & Young as independent auditor for fiscal year 2025 with 32,364,505 votes for, 132,459 against.
Approved amendment increasing authorized non-voting common stock from 12,850,259 to 112,850,259 shares.

item 5.02 item 5.07

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Paul Scherer

Class III Director

PRLD · Prelude Therapeutics Inc

Effective: 2025-06-12
Filed: June 13, 2025, 7:59 PM ET

the Board appointed Paul Scherer, M.D., as a Class III director and as a member of the Compensation committee and the Governance Committee of the Board, effective as of the adjournment of the 2025 Annual Meeting of Stockholders (the “ Annual Meeting ”) on June 12, 2025

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Paul Scherer was appointed as Class III Director at Prelude Therapeutics Inc.

Action: appointed
Role: Class III Director

Exact text from the filing

the Board appointed Paul Scherer, M.D., as a Class III director and as a member of the Compensation committee and the Governance Committee of the Board, effective as of the adjournment of the 2025 Annual Meeting of Stockholders (the “ Annual Meeting ”) on June 12, 2025

View on SEC.gov

Prelude Therapeutics Inc filing history →

Source: SEC EDGAR

accession 0000950170-25-086170

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.